PIK3CA

About

Location: 3q26.32

Mappings

HGNC: HGNC:8975

Ensembl: ENSG00000121879

NCBI: 5290

Refseq: NM_006218.4

View API

Biomarkers

PIK3CA is involved in the following curated biomarkers.

Name Biomarker type Propositions Statements
PIK3CA oncogenic variants Somatic variant 9 16
PIK3CA amplification Copy number 1 1

Therapeutic response

Precision oncology relationships for therapeutic response involving this gene.

Organizations
Biomarkers
Cancer types
Therapies
Organizations Biomarkers Cancer types Therapies
EMA (1) FDA (2) ER positive, HER2-negative, PIK3CA oncogenic variants Invasive Breast Carcinoma Alpelisib, Fulvestrant
EMA (1) FDA (2) HER2-negative, PIK3CA oncogenic variants, PR positive Invasive Breast Carcinoma Alpelisib, Fulvestrant
EMA (1) FDA (2) ER positive, HER2-negative, PIK3CA oncogenic variants, PR positive Invasive Breast Carcinoma Alpelisib, Fulvestrant
EMA (1) FDA (2) ER positive, HER2-negative, PIK3CA oncogenic variants Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (2) HER2-negative, PIK3CA oncogenic variants, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (2) ER positive, HER2-negative, PIK3CA oncogenic variants, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant
EMA (1) FDA (2) ER positive, HER2-negative, PIK3CA oncogenic variants Invasive Breast Carcinoma Fulvestrant, Inavolisib, Palbociclib
EMA (1) FDA (2) HER2-negative, PIK3CA oncogenic variants, PR positive Invasive Breast Carcinoma Fulvestrant, Inavolisib, Palbociclib
EMA (1) FDA (2) ER positive, HER2-negative, PIK3CA oncogenic variants, PR positive Invasive Breast Carcinoma Fulvestrant, Inavolisib, Palbociclib
EMA (1) ER positive, HER2-negative, PIK3CA amplification Invasive Breast Carcinoma Capivasertib, Fulvestrant